BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Paciotti S, Bellomo G, Gatticchi L, Parnetti L. Are We Ready for Detecting α-Synuclein Prone to Aggregation in Patients? The Case of "Protein-Misfolding Cyclic Amplification" and "Real-Time Quaking-Induced Conversion" as Diagnostic Tools. Front Neurol 2018;9:415. [PMID: 29928254 DOI: 10.3389/fneur.2018.00415] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 12.8] [Reference Citation Analysis]
Number Citing Articles
1 Bellomo G, Paciotti S, Concha-marambio L, Rizzo D, Gatticchi L, Cerofolini L, Giuntini S, De Luca CMG, Ma Y, Farris CM, Pieraccini G, Bologna S, Filidei M, Ravera E, Lelli M, Moda F, Fragai M, Parnetti L, Luchinat C. Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays.. [DOI: 10.21203/rs.3.rs-2001732/v1] [Reference Citation Analysis]
2 Faldu KG, Shah JS. Alzheimer's disease: a scoping review of biomarker research and development for effective disease diagnosis. Expert Rev Mol Diagn 2022. [PMID: 35855631 DOI: 10.1080/14737159.2022.2104639] [Reference Citation Analysis]
3 Goto Y, Noji M, Nakajima K, Yamaguchi K. Supersaturation-Dependent Formation of Amyloid Fibrils. Molecules 2022;27:4588. [DOI: 10.3390/molecules27144588] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wang Y, Hu J, Chen X, Wang S, Zhang C, Hu J, Guo D, Liu X. Real-time quaking-induced conversion assay is accurate for Lewy body diseases: a meta-analysis. Neurol Sci 2022;43:4125-4132. [DOI: 10.1007/s10072-022-06014-x] [Reference Citation Analysis]
5 Tsirkou A, Kaczorowski F, Verdurand M, Raffoul R, Pansieri J, Quadrio I, Chauveau F, Antoine R. Charge detection mass spectrometry on human-amplified fibrils from different synucleinopathies. Chem Commun (Camb) 2022;58:7192-5. [PMID: 35670578 DOI: 10.1039/d2cc00200k] [Reference Citation Analysis]
6 Vidović M, Rikalovic MG. Alpha-Synuclein Aggregation Pathway in Parkinson's Disease: Current Status and Novel Therapeutic Approaches. Cells 2022;11:1732. [PMID: 35681426 DOI: 10.3390/cells11111732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Munoz Ospina B, Quintana-peña V, Alvarez D, A. Valderrama J, Takeuchi Y, L. Orozco J. Perspectives of Cognitive Impairment and Behavioral Disturbances in Parkinson’s Disease Dementia. Dementia in Parkinson’s Disease - Everything you Need to Know 2022. [DOI: 10.5772/intechopen.96623] [Reference Citation Analysis]
8 Pons M, Loftus N, Vialaret J, Moreau S, Lehmann S, Hirtz C. Proteomics Challenges for the Assessment of Synuclein Proteoforms as Clinical Biomarkers in Parkinson’s Disease. Front Aging Neurosci 2022;14:818606. [DOI: 10.3389/fnagi.2022.818606] [Reference Citation Analysis]
9 Giampietri L, Belli E, Beatino MF, Giannoni S, Palermo G, Campese N, Tognoni G, Siciliano G, Ceravolo R, De Luca C, Baldacci F. Fluid Biomarkers in Alzheimer’s Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments. Diagnostics 2022;12:796. [DOI: 10.3390/diagnostics12040796] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
10 Al-Azzani M, König A, Outeiro TF. Production of Recombinant Alpha-Synuclein: Still No Standardized Protocol in Sight. Biomolecules 2022;12:324. [PMID: 35204823 DOI: 10.3390/biom12020324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Barba L, Paolini Paoletti F, Bellomo G, Gaetani L, Halbgebauer S, Oeckl P, Otto M, Parnetti L. Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers. Movement Disorders. [DOI: 10.1002/mds.28941] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
12 Srivastava A, Kataria A, Yadav DK, Han I, Choi E. Interplay of alpha-synuclein pathology and gut microbiome in Parkinson’s disease. Human-Gut Microbiome 2022. [DOI: 10.1016/b978-0-323-91313-3.00003-9] [Reference Citation Analysis]
13 Chethana HP, Hemachandra G, Sidhu A. Biomarkers: Potential Perspectives in Detection, Diagnosis, and Prognosis of Neurodegenerative Disorders. Functional Foods and Therapeutic Strategies for Neurodegenerative Disorders 2022. [DOI: 10.1007/978-981-16-6703-9_12] [Reference Citation Analysis]
14 Goto Y, Nakajima K, Yamaguchi K, So M, Ikenaka K, Mochizuki H, Ogi H. Development of HANABI, an ultrasonication-forced amyloid fibril inducer. Neurochem Int 2021;153:105270. [PMID: 34954259 DOI: 10.1016/j.neuint.2021.105270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Pathak N, Vimal SK, Tandon I, Agrawal L, Hongyi C, Bhattacharyya S. Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment. Metab Brain Dis 2021. [PMID: 34719771 DOI: 10.1007/s11011-021-00800-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
16 Malfertheiner K, Stefanova N, Heras-Garvin A. The Concept of α-Synuclein Strains and How Different Conformations May Explain Distinct Neurodegenerative Disorders. Front Neurol 2021;12:737195. [PMID: 34675870 DOI: 10.3389/fneur.2021.737195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, Weintraub D. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 2021;7:47. [PMID: 34210995 DOI: 10.1038/s41572-021-00280-3] [Cited by in Crossref: 75] [Cited by in F6Publishing: 85] [Article Influence: 75.0] [Reference Citation Analysis]
18 Figura M, Sitkiewicz E, Świderska B, Milanowski Ł, Szlufik S, Koziorowski D, Friedman A. Proteomic Profile of Saliva in Parkinson's Disease Patients: A Proof of Concept Study. Brain Sci 2021;11:661. [PMID: 34070185 DOI: 10.3390/brainsci11050661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
19 Bhumkar A, Magnan C, Lau D, Jun ESW, Dzamko N, Gambin Y, Sierecki E. Single‐Molecule Counting Coupled to Rapid Amplification Enables Detection of α‐Synuclein Aggregates in Cerebrospinal Fluid of Parkinson's Disease Patients. Angew Chem 2021;133:11981-11990. [DOI: 10.1002/ange.202014898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Combi R, Salsone M, Villa C, Ferini-Strambi L. Genetic Architecture and Molecular, Imaging and Prodromic Markers in Dementia with Lewy Bodies: State of the Art, Opportunities and Challenges. Int J Mol Sci 2021;22:3960. [PMID: 33921279 DOI: 10.3390/ijms22083960] [Reference Citation Analysis]
21 Bhumkar A, Magnan C, Lau D, Jun ESW, Dzamko N, Gambin Y, Sierecki E. Single-Molecule Counting Coupled to Rapid Amplification Enables Detection of α-Synuclein Aggregates in Cerebrospinal Fluid of Parkinson's Disease Patients. Angew Chem Int Ed Engl 2021;60:11874-83. [PMID: 33511725 DOI: 10.1002/anie.202014898] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
22 Castonguay AM, Gravel C, Lévesque M. Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions. J Parkinsons Dis 2021;11:71-92. [PMID: 33104039 DOI: 10.3233/JPD-202221] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
23 Shahnawaz M, Soto C. Identification of biomarkers for diagnosing and monitoring therapy in the treatment of neurologic disorders. Neurotherapeutics in the Era of Translational Medicine 2021. [DOI: 10.1016/b978-0-12-816475-4.00020-3] [Reference Citation Analysis]
24 Gaetani L, Paolini Paoletti F, Bellomo G, Mancini A, Simoni S, Di Filippo M, Parnetti L. CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. Trends Pharmacol Sci 2020;41:1023-37. [PMID: 33127098 DOI: 10.1016/j.tips.2020.09.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
25 Bougea A. Synuclein in neurodegeneration. Adv Clin Chem 2021;103:97-134. [PMID: 34229853 DOI: 10.1016/bs.acc.2020.08.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
26 Farotti L, Paolini Paoletti F, Simoni S, Parnetti L. Unraveling Pathophysiological Mechanisms of Parkinson's Disease: Contribution of CSF Biomarkers. Biomark Insights 2020;15:1177271920964077. [PMID: 33110345 DOI: 10.1177/1177271920964077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Marrero-Winkens C, Sankaran C, Schätzl HM. From Seeds to Fibrils and Back: Fragmentation as an Overlooked Step in the Propagation of Prions and Prion-Like Proteins. Biomolecules 2020;10:E1305. [PMID: 32927676 DOI: 10.3390/biom10091305] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
28 d'Abramo C, D'Adamio L, Giliberto L. Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use. J Pers Med 2020;10:E116. [PMID: 32911755 DOI: 10.3390/jpm10030116] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
29 Dong X, Zheng D, Nao J. Circulating Exosome microRNAs as Diagnostic Biomarkers of Dementia. Front Aging Neurosci 2020;12:580199. [PMID: 33093831 DOI: 10.3389/fnagi.2020.580199] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
30 Schaeffer E, Kluge A, Böttner M, Zunke F, Cossais F, Berg D, Arnold P. Alpha Synuclein Connects the Gut-Brain Axis in Parkinson's Disease Patients - A View on Clinical Aspects, Cellular Pathology and Analytical Methodology. Front Cell Dev Biol 2020;8:573696. [PMID: 33015066 DOI: 10.3389/fcell.2020.573696] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 13.0] [Reference Citation Analysis]
31 Lee M, Liu K, Thomas JL, Su Z, O’hare D, van Wuellen T, Chamarro JM, Bolognin S, Luo S, Schwamborn JC, Lin H. Peptide-Imprinted Poly(hydroxymethyl 3,4-ethylenedioxythiophene) Nanotubes for Detection of α Synuclein in Human Brain Organoids. ACS Appl Nano Mater 2020;3:8027-36. [DOI: 10.1021/acsanm.0c01476] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
32 Maass F, Rikker S, Dambeck V, Warth C, Tatenhorst L, Csoti I, Schmitz M, Zerr I, Leha A, Bähr M, Lingor P. Increased alpha-synuclein tear fluid levels in patients with Parkinson's disease. Sci Rep 2020;10:8507. [PMID: 32444780 DOI: 10.1038/s41598-020-65503-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
33 Surguchov A. Analysis of Protein Conformational Strains-A Key for New Diagnostic Methods of Human Diseases. Int J Mol Sci 2020;21:E2801. [PMID: 32316500 DOI: 10.3390/ijms21082801] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
34 Zetterberg H, Bendlin BB. Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies. Mol Psychiatry 2021;26:296-308. [PMID: 32251378 DOI: 10.1038/s41380-020-0721-9] [Cited by in Crossref: 107] [Cited by in F6Publishing: 119] [Article Influence: 53.5] [Reference Citation Analysis]
35 Simrén J, Ashton NJ, Blennow K, Zetterberg H. An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. Curr Opin Neurobiol 2020;61:29-39. [PMID: 31838254 DOI: 10.1016/j.conb.2019.11.019] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 14.3] [Reference Citation Analysis]
36 Chatterjee D, Kordower JH. Immunotherapy in Parkinson’s disease: Current status and future directions. Neurobiology of Disease 2019;132:104587. [DOI: 10.1016/j.nbd.2019.104587] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
37 Stott SRW, Wyse RK, Brundin P. Novel approaches to counter protein aggregation pathology in Parkinson's disease. Prog Brain Res 2020;252:451-92. [PMID: 32247372 DOI: 10.1016/bs.pbr.2019.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Manne S, Kondru N, Jin H, Anantharam V, Huang X, Kanthasamy A, Kanthasamy AG. α-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson's disease patients. Mov Disord 2020;35:268-78. [PMID: 31758740 DOI: 10.1002/mds.27907] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 18.0] [Reference Citation Analysis]
39 Bellomo G, Paciotti S, Gatticchi L, Parnetti L. The Vicious Cycle Between α ‐Synuclein Aggregation and Autophagic‐Lysosomal Dysfunction. Mov Disord 2020;35:34-44. [DOI: 10.1002/mds.27895] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 15.0] [Reference Citation Analysis]
40 Ross OA, Mata IF. Driving genotype treatment options down the right path(way). Mov Disord 2019;34:1811-3. [PMID: 31654424 DOI: 10.1002/mds.27893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Li T, Le W. Biomarkers for Parkinson's Disease: How Good Are They? Neurosci Bull 2020;36:183-94. [PMID: 31646434 DOI: 10.1007/s12264-019-00433-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
42 Nicot S, Verchère J, Bélondrade M, Mayran C, Bétemps D, Bougard D, Baron T. Seeded propagation of α-synuclein aggregation in mouse brain using protein misfolding cyclic amplification. FASEB J 2019;33:12073-86. [PMID: 31370680 DOI: 10.1096/fj.201900354R] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
43 García‐ayllón M, Monge‐argilés J, Monge‐garcía V, Navarrete F, Cortés‐gómez M, Sánchez‐payá J, Manzanares J, Gasparini‐berenguer R, Leiva‐santana C, Sáez‐valero J. Measurement of CSF α‐synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer’s disease. J Neurochem 2019;150:218-30. [DOI: 10.1111/jnc.14719] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
44 Schwarzman AL, Senkevich KA, Emelyanov AK, Pchelina SN. Prion Properties of Alpha-Synuclein. Mol Biol 2019;53:335-41. [DOI: 10.1134/s002689331903018x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
45 Bellomo G, Bologna S, Cerofolini L, Paciotti S, Gatticchi L, Ravera E, Parnetti L, Fragai M, Luchinat C. Dissecting the Interactions between Human Serum Albumin and α-Synuclein: New Insights on the Factors Influencing α-Synuclein Aggregation in Biological Fluids. J Phys Chem B 2019;123:4380-6. [PMID: 31034772 DOI: 10.1021/acs.jpcb.9b02381] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
46 Parnetti L, Paciotti S, Farotti L, Bellomo G, Sepe FN, Eusebi P. Parkinson's and Lewy body dementia CSF biomarkers. Clin Chim Acta 2019;495:318-25. [PMID: 31051162 DOI: 10.1016/j.cca.2019.04.078] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
47 Kakuda K, Ikenaka K, Araki K, So M, Aguirre C, Kajiyama Y, Konaka K, Noi K, Baba K, Tsuda H, Nagano S, Ohmichi T, Nagai Y, Tokuda T, El-Agnaf OMA, Ogi H, Goto Y, Mochizuki H. Ultrasonication-based rapid amplification of α-synuclein aggregates in cerebrospinal fluid. Sci Rep 2019;9:6001. [PMID: 30979935 DOI: 10.1038/s41598-019-42399-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
48 Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P. CSF and blood biomarkers for Parkinson's disease. Lancet Neurol 2019;18:573-86. [PMID: 30981640 DOI: 10.1016/S1474-4422(19)30024-9] [Cited by in Crossref: 198] [Cited by in F6Publishing: 233] [Article Influence: 66.0] [Reference Citation Analysis]
49 Kang UJ, Boehme AK, Fairfoul G, Shahnawaz M, Ma TC, Hutten SJ, Green A, Soto C. Comparative study of cerebrospinal fluid α-synuclein seeding aggregation assays for diagnosis of Parkinson's disease. Mov Disord 2019;34:536-44. [PMID: 30840785 DOI: 10.1002/mds.27646] [Cited by in Crossref: 81] [Cited by in F6Publishing: 86] [Article Influence: 27.0] [Reference Citation Analysis]
50 Niu H, Shen L, Li T, Ren C, Ding S, Wang L, Zhang Z, Liu X, Zhang Q, Geng D, Wu X, Li H. Alpha-synuclein overexpression in the olfactory bulb initiates prodromal symptoms and pathology of Parkinson's disease. Transl Neurodegener 2018;7:25. [PMID: 30356861 DOI: 10.1186/s40035-018-0128-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 8.5] [Reference Citation Analysis]